10-Q: IMAC Holdings Reports Q2 2025 Results

IMAC Holdings reports a net loss of $2.1 million for Q2 2025, focusing on precision medicine in cancer treatment.

Summary

• IMAC Holdings, Inc. reported financial results for the quarter ended June 30, 2025.
• The company's continuing operations are focused on precision medicine in cancer treatment based on activated protein analysis.
• Net revenue for the quarter was $0.
• Net loss for the quarter was $2.1 million, including a $2.1 million loss from continuing operations.
• For the six months ended June 30, 2025, net revenue was $0.002 million.
• Net loss for the six months was $4.3 million, including a $4.3 million loss from continuing operations.
• Legal fees for the six months totaled $0.6 million.
• As of June 30, 2025, the company had $0.04 million in cash and a working capital deficit of $10.6 million.
• The company issued promissory notes totaling $2,432,000 during the six months ended June 30, 2025.
• The company's management team has determined that its financial condition raises substantial doubt as to its ability to continue as a going concern.

Sentiment

Score: 2

Explanation: The filing contains mostly negative information, including significant losses, a large working capital deficit, and doubt about the company's ability to continue as a going concern. There are some positives, such as the focus on a growing industry and the acquisition of laboratory capabilities, but the overall sentiment is negative.

Positives

• The company is focusing on precision medicine in cancer treatment, which could be a high-growth area.
• The company acquired laboratory capabilities from Theralink Technologies, Inc., providing technical capabilities and intellectual property licenses.
• During the six months ended June 30, 2025, 4,455 shares of preferred stock were converted into 1,425,170 shares of common stock.
• Net cash provided by financing activities during the six months ended June 30, 2025 was $1.9 million, which was primarily proceeds from the sale of common stock and issuance of promissory notes.

Negatives

• The company had no net revenue for the three months ended June 30, 2025.
• The company had a net loss of $2.1 million for the three months ended June 30, 2025.
• The company has a significant working capital deficit of $10.6 million as of June 30, 2025.
• The company has an accumulated deficit of $69.3 million as of June 30, 2025.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company's disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal control over financial reporting.
• The company has significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information.

Risks

• The company's ability to obtain additional financing for the projected costs associated with the growth of its recently acquired laboratory.
• The company's ability to attract competent, skilled laboratory and sales personnel for its operations at acceptable prices to manage its overhead.
• The company may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on its financial condition and could force the company to delay, limit, reduce or terminate its development or acquisition activity.
• Failure to receive additional funding could also cause the company to cease operations, in part or in full.
• The company is subject to audits under various governmental programs in which third party firms engaged by the Center for Medicare & Medicaid Services (CMS) conduct extensive reviews of claims data to identify potential improper payments.
• The company is involved in legal proceedings related to overpayment requests from CMS, which could have a material impact on the company's financial condition, results of operations or liquidity.

Future Outlook

The company anticipates needing to raise additional capital to fund future operations. The company may seek additional capital due to favorable market conditions or strategic considerations.

Management Comments

• Management plans to raise additional capital through the issuance of financial instruments including both debt and equity to mitigate the conditions and events that raise substantial doubt.
• Management will continue to observe and assess our internal accounting function and make necessary improvements whenever they may be required.

Industry Context

The company is operating in the precision medicine and cancer treatment industry, which is a rapidly growing field. The company's focus on activated protein analysis could give it a competitive advantage.

Comparison to Industry Standards

• It is difficult to compare IMAC Holdings directly to industry standards due to its unique business model and focus on precision medicine in cancer treatment.
• Comparable companies in the diagnostics and personalized medicine space include Exact Sciences, Foundation Medicine (Roche), and Guardant Health.
• These companies have significantly higher revenue and market capitalization than IMAC Holdings.
• IMAC Holdings' reliance on raising additional capital is a concern, as many successful companies in this space have strong revenue growth and positive cash flow.

Legal Proceedings

• The Company pursued the next step of its appeal of the alleged overpayment by filing a lawsuit in federal court on May 14, 2025.
• In October 2021, the Company received notification from Covent Bridge Group (Covent Bridge), a CMS contractor, that they are recommending to CMS that the Company was overpaid and a request for payment was made in December 2021 in the amount of approximately $ 2.7 million related to Progressive Health.
• In May 2022 the Company received notifications from Covent Bridge, that they are recommending to CMS that the Company was overpaid and a request for payment was made in the amount of approximately $ 0.5 million related to Advantage Therapy.
• In November 2024, the Company received notification from Covent Bridge, that it estimates the Company was overpaid CMS funds in the amount of approximately $ 1.1 million at a patient center in Missouri (IMAC St. Louis).

Stakeholder Impact

• Shareholders: The company's financial condition raises substantial doubt about its ability to continue as a going concern, which could negatively impact shareholder value.
• Employees: The company may need to reduce its workforce if it is unable to raise additional capital.
• Customers: The company's ability to provide services may be impacted if it is unable to raise additional capital.
• Creditors: The company may have difficulty repaying its debts if it is unable to raise additional capital.

Next Steps

• The company needs to raise additional capital to fund future operations.
• The company needs to improve its internal control over financial reporting.
• The company needs to resolve the legal proceedings related to overpayment requests from CMS.
• The company needs to attract competent, skilled laboratory and sales personnel for its operations at acceptable prices to manage its overhead.

Key Dates

Recommendation

The company's financial condition raises substantial doubt about its ability to continue as a going concern. The company has significant losses, a large working capital deficit, and material weaknesses in its internal control over financial reporting. The company is also involved in legal proceedings related to overpayment requests from CMS. These factors make the stock a high-risk investment.

Keywords

IMAC Holdings, Ignite Proteomics, precision medicine, cancer treatment, RPPA technology, financial results, SEC filing, Form 10-Q, going concern, Theralink Technologies